Human quercetin pharmacokinetic studies show women achieve modestly higher plasma levels than men at equivalent doses (~15–20% higher Cmax and AUC), potentially due to lower body mass and CYP metabolism differences. Despite this, dosing recommendations in clinical trials have not been sex-differentiated; standard recommendations apply to both sexes with individual optimization.

Is quercetin safe during perimenopause?

Yes. Quercetin's weak estrogenic activity is not clinically significant and does not appear to affect perimenopausal hormone levels. Its anti-inflammatory and cardiovascular protective effects are particularly beneficial during this hormonal transition.

Do men and women need different quercetin protocols?

The fundamental protocol is similar: continuous low-dose (200–300 mg/day) for maintenance, burst dosing (500–1,000 mg for 2 days monthly) for senolytic purposes. Women may achieve adequate effects at the lower end of the dose range.